Study of DS-8201a in HER2-Low, Unresectable and/or Metastatic Breast Cancer

Mammella HER2+: gli antibody drug conjugateПодробнее

T-DXd; DS-8201a in subjects with HER2-positive metastatic breast cancer previously treated with ...Подробнее

DS-8201 + pembro in patients HER2+ breast and NSCLCПодробнее

Dr. Iwata Discusses DS-8201a in HER2+ Breast CancerПодробнее

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expressionПодробнее

DS-8201 Safety Profile, Activity in HER2-expressing Breast CancerПодробнее

Study of Targeted Therapy for HER2-Positive Metastatic Breast CancerПодробнее

Clinical outcomes in women with metastatic HER2-low breast cancer in the real worldПодробнее

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer ptsПодробнее

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patientsПодробнее

Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBCПодробнее

Remaining questions surrounding HER2-low breast cancer – how low can you go?Подробнее

Advances in HER2-positive and HER2-low Breast CancerПодробнее

HER2-low expression in breast cancerПодробнее

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJMПодробнее

Study of Atezolizumab with Pertuzumab and Trastuzumab in HER2- Positive Metastatic Breast CancerПодробнее

DESTINY-Breast04: practice-changing results for HER2-low breast cancerПодробнее

Is HER2-low a distinct subtype of breast cancer?Подробнее

ASCO 2022: Trastuzumab deruxtecan vs. treatment of physician's choice in HER2-low unresectable a...Подробнее

Questions remaining in the field of HER2-low breast cancerПодробнее